Ranbaxy announced the launch of Cevimeline HCl Capsules, the generic version of Daiichi Sankyo‘s Evoxac.

Cevimeline HCl is a cholinergic agonist indicated for the treatment of symptoms of dry mouth associated with Sjogren’s syndrome, an autoimmune disorder affecting the moisture-producing glands. Cevimeline HCl binds to muscarinic receptors that increase secretion of exocrine glands, such as salivary and sweat glands, and increase smooth muscle tone in the GI and urinary tracts. Cevimeline HCl specifically acts at the M3 receptors, located on the salivary gland epithelia.

Cevimeline HCl is available in 30mg strength capsules.

For more information call (609) 720-9200 or visit www.ranbaxyusa.com.